Ketamine for PTSD: Long-Term Brain Effects and Connectivity

Ketamine triggers measurable changes in brain structure and functional connectivity that are directly relevant to the neural circuits disrupted by PTSD. In animal models, a single dose can increase the formation of new dendritic spines in the prefrontal cortex within hours, and in human imaging studies, ketamine shifts activity patterns in networks that govern emotional regulation, threat processing, and self-referential thought. These effects overlap strikingly with the very circuits that malfunction in PTSD, which is part of what makes the drug so interesting to researchers. But the picture is more complicated than “ketamine repairs the PTSD brain,” and the timeline, durability, and individual variability of these changes all matter.

How PTSD Reshapes Brain Circuits

To understand what ketamine does to the brain over the long term, you first need to know what PTSD does. The disorder is characterized by abnormal activation in the amygdala and disrupted communication between the amygdala and the prefrontal cortex, which is the part of the brain responsible for putting the brakes on fear responses.¹ In a healthy brain, the prefrontal cortex sends signals that help regulate emotional reactions. In PTSD, that top-down control weakens, and the amygdala becomes hyperreactive. People startle more easily, experience intrusive fear and emotional flooding, and have trouble distinguishing real danger from harmless triggers.

This is not just a metaphor. Functional neuroimaging consistently shows that these corticolimbic circuits operate differently in people with PTSD compared to trauma-exposed controls who did not develop the disorder. Chronic stress also damages the prefrontal cortex at a cellular level, reducing the density of dendritic spines, which are the tiny protrusions on neurons where synaptic connections form. Fewer spines means fewer connections, which means weaker circuit function. Ketamine’s relevance to PTSD starts here: the drug appears to reverse some of these specific structural and functional deficits.

Spine Formation and Synaptic Rebuilding

The most striking brain effect of ketamine is its ability to rapidly promote the growth of new synaptic connections in the prefrontal cortex. In rat studies, ketamine activated a cellular growth pathway called mTOR, which led to increases in synaptic signaling proteins and the formation of new spine synapses. Blocking mTOR completely eliminated both the new spine growth and ketamine’s antidepressant-like behavioral effects, confirming that spine formation is central to what the drug does.² The researchers noted that these synaptic effects are essentially the opposite of what chronic stress does to the same brain region, which is a key insight for PTSD specifically.

The mechanism involves a chain reaction. Ketamine blocks a type of receptor on neurons, which paradoxically leads to a burst of the neurotransmitter glutamate. That glutamate activates a different set of receptors, which in turn triggers the release of brain-derived neurotrophic factor (BDNF), a growth protein that drives the mTOR pathway and the construction of new synapses.³

The timeline of this process is revealing. In mouse studies, ketamine enhanced the formation of new spines within two to four hours, matching the window when behavioral improvements first appeared. But the actual increase in total spine density did not peak until about 12 hours later, suggesting that the drug first opens a window of heightened plasticity, and then the brain slowly fills that window with new connections.⁴ Longitudinal imaging in mice confirmed that the elevated spine density in the medial frontal cortex persisted for days after a single injection, driven primarily by an increased rate of spine formation rather than a decreased rate of spine loss.⁵

There is a counterintuitive wrinkle, though. The same longitudinal study found that ketamine caused a small, short-term loss of about 10% of the length of certain dendritic branches on the first day after injection. So the drug both trims some existing architecture and builds new connections. Researchers interpret this as a kind of remodeling: pruning old, potentially dysfunctional connections while encouraging new ones to form in their place.⁵

Work in mice exposed to chronic stress has put this into sharper focus. Ketamine did not simply add spines indiscriminately; it selectively rescued spines that had been eliminated by stress and restored coordinated activity in groups of neurons that predicted motivated behavior.⁶ That finding is particularly relevant for PTSD, where the loss of prefrontal control is a core feature of the disorder.

What Changes in Functional Connectivity

Beyond microscopic spine growth, ketamine alters how large-scale brain networks communicate with one another. In PTSD, two networks are of particular interest: the default mode network (DMN), which is active during self-referential thought and mind-wandering, and the somatosensory network, which processes bodily sensations. A 2025 study used a computational framework to compare brain dynamics under ketamine and in PTSD patients before and after therapy. Both ketamine and therapeutic intervention shifted brain dynamics in a similar direction: the DMN became more dominant, while somatosensory network activity decreased.⁷ The parallel between ketamine’s acute effects and the outcomes of longer-term PTSD therapy suggests the drug may be pushing the brain toward a state that therapy achieves more gradually.

Ketamine also reduces reactivity in the amygdala and hippocampus during emotional processing. In one study, the drug dampened the response of the amygdala-hippocampal complex to emotionally charged images, and the degree of this dampening correlated with how strongly the amygdala was connected to a key prefrontal region at rest.⁸ For someone with PTSD, where the amygdala fires too readily in response to trauma reminders, this kind of dampening is precisely the effect you would want.

Not all the connectivity findings have been straightforward, though. A randomized pilot study in PTSD patients found that ketamine did not increase resting-state connectivity between the amygdala and the medial prefrontal cortex as the researchers had predicted. Instead, it temporarily decreased connectivity between a specific prefrontal subregion and the amygdala, the opposite of what was expected.⁹ This suggests the relationship between ketamine and prefrontal-amygdala connectivity is not as simple as “the drug strengthens the circuit that PTSD weakens.” The acute disconnection might be part of the therapeutic process, perhaps allowing the circuit to reset before reconnecting in a healthier pattern. But this is speculative territory, and the evidence is still thin.

How Long the Brain Changes Last

This is arguably the most important question for anyone considering ketamine treatment, and the honest answer is that the structural brain changes outlast the clinical relief by an unclear margin. In the mouse studies described earlier, increased spine density persisted for several days after a single injection. But clinical trials in humans tell a more sobering story about how long symptom improvement actually holds.

A study of repeated ketamine infusions for people with both PTSD and treatment-resistant depression found that those who achieved remission from PTSD had a median time to relapse of 41 days after completing the infusion series.¹⁰ A randomized controlled trial of repeated ketamine specifically for chronic PTSD reported an even shorter window: among those who responded, the median time to loss of response was about four weeks after the two-week infusion course ended.¹¹

So even though ketamine builds new synaptic connections that may persist for weeks, the clinical benefits tend to fade within roughly a month for most people. This gap raises important questions. It may be that the new spines formed under ketamine are not yet stable enough to maintain the circuit improvements on their own. Or it may be that structural plasticity alone is not enough without behavioral reinforcement. Trauma-related neural patterns are deeply entrenched, and new synapses that are not repeatedly activated may simply be pruned away again. This is one reason researchers are interested in combining ketamine with psychotherapy: the drug opens a plasticity window, and therapy may help consolidate the new connections by actively engaging the relevant circuits during that window.

Quieting Neuroinflammation

PTSD is increasingly understood as a disorder with an inflammatory component. People with PTSD show elevated levels of pro-inflammatory molecules in the brain and the bloodstream, and this chronic low-grade inflammation appears to contribute to the neural damage in the prefrontal cortex and hippocampus. Ketamine seems to directly address this.

In a mouse model of PTSD, animals exposed to foot shocks showed increased activation of microglia (the brain’s resident immune cells) and elevated levels of the inflammatory molecules IL-6 and TNF-alpha in the medial prefrontal cortex. Subanesthetic doses of esketamine, one form of the drug, significantly reduced both the microglial activation and the inflammatory signaling, and this reduction tracked with improvement in PTSD-like behaviors.¹² The same study found that esketamine also normalized abnormalities in myelination, the insulating coating on nerve fibers that speeds signal transmission. Disrupted myelination may be another underappreciated feature of PTSD’s brain pathology.

A human study of oral ketamine for PTSD examined immune gene expression over time and found something more nuanced. In the short term, ketamine appeared to suppress inflammatory pathways, including interferon and cytokine storm signaling. But over a longer period, the drug seemed to shift the immune system toward sustained remodeling rather than just acute suppression, with changes in key regulatory molecules that persisted beyond the initial anti-inflammatory effect.¹³ This two-phase immune effect could be relevant to the drug’s longer-term brain impact: if ketamine is not just temporarily dampening inflammation but actually recalibrating the immune response, that could help protect new synapses from being damaged by ongoing inflammatory processes.

White Matter and Structural Connectivity

Most discussion of ketamine’s brain effects focuses on gray matter, the neuron-dense regions where synapses form. But the white matter tracts that connect distant brain regions also matter, and there is early evidence that ketamine changes these too. A study using advanced diffusion imaging in patients with treatment-resistant depression found that a series of ketamine infusions led to significant decreases in neurite density within white matter pathways connecting the occipital and temporal lobes.¹⁴ Changes in neurite density within tracts connecting the basal ganglia, thalamus, and cortex correlated with improvements in anhedonia, the inability to feel pleasure.

This is notable because white matter changes are thought to reflect longer-term structural reorganization compared to the relatively rapid formation and loss of dendritic spines. The study was conducted in depression rather than PTSD specifically, so the findings do not translate directly. But because PTSD and depression share overlapping neural circuit disruptions and frequently co-occur, the white matter findings suggest that ketamine’s structural effects extend beyond the synaptic level into the brain’s broader wiring architecture.

Cognitive Safety Over Repeated Use

One of the most common concerns about ketamine is whether repeated use harms cognition, given the drug’s well-documented effects as a dissociative anesthetic and its potential for misuse. The available evidence on therapeutic dosing is reassuring, at least in the short to medium term. A study of repeated ketamine infusions in patients with comorbid PTSD and depression found no significant worsening on any cognitive measure. In fact, working memory improved after the infusion series was completed.¹⁵

A systematic review of neurocognitive effects at subanesthetic doses across depression, PTSD, and healthy subjects reinforced this picture, finding that therapeutic ketamine did not produce significant cognitive impairment in patients with depression or PTSD. The review noted that any procognitive effects seemed most pronounced in executive function, which aligns with what we know about ketamine’s synaptic effects in the prefrontal cortex.¹⁶ The irony is that healthy subjects actually showed more acute cognitive disruption from ketamine than people with depression or PTSD, which may reflect the fact that the drug is correcting a deficit in the patient group while simply perturbing a normally functioning system in the healthy group.

These findings apply to controlled therapeutic use at low doses. Chronic recreational ketamine abuse at much higher doses is a different matter entirely and is associated with well-documented cognitive and bladder toxicity. The distinction between supervised subanesthetic dosing and unsupervised heavy use is critical and sometimes gets blurred in public discussion.

Why Genetics Influence the Response

Not everyone’s brain responds to ketamine the same way, and genetics is one reason. A key gene in this story codes for BDNF, the growth factor at the center of ketamine’s synaptic rebuilding mechanism. A common variant of this gene, known as Val66Met, reduces the release of BDNF. In mouse models, animals carrying the Met version of this gene showed smaller and fewer dendritic spines in the prefrontal cortex at baseline, along with weaker synaptic currents.¹⁷ Because ketamine’s effects depend on the BDNF-mTOR cascade, a genetic variant that weakens BDNF signaling could blunt the drug’s ability to drive spine growth, potentially explaining why some people get a robust response and others do not.

Roughly a third of people of European ancestry carry at least one copy of the Met variant, and the frequency is even higher in some Asian populations. This means a sizable minority of potential ketamine patients may have a biological headwind working against them. It does not mean the drug will not work for carriers of this variant, but it may mean they need different dosing, more sessions, or combination approaches to achieve the same synaptic effects.

Sex Differences in Brain Response

Animal research has revealed that male and female brains respond to ketamine on different timelines and at different doses. Female mice showed antidepressant-like effects at lower ketamine doses than males and responded more quickly, within 30 minutes of injection. However, the sustained effects lasting days after a single dose were actually more pronounced in males.¹⁸ The study also found that glutamate levels and serotonin activity in the prefrontal cortex and hippocampus changed differently depending on sex, suggesting the underlying neurochemistry of ketamine’s action varies between males and females.

These findings are from mice, not humans, and direct translation is always uncertain. But they raise important questions about whether ketamine dosing protocols optimized in predominantly male study populations are actually ideal for women. Most clinical trials of ketamine for PTSD have not been powered to detect sex-based differences in treatment response, so this remains a significant gap in the evidence.

Epigenetic Effects That Could Outlast the Drug

Some of ketamine’s longer-lasting brain changes may operate at the level of gene expression rather than synaptic structure. A systematic review of preclinical studies found that ketamine modulates how genes are read by the cell, specifically by altering chemical marks on the proteins that package DNA (histone acetylation and methylation). These modifications can boost the expression of genes related to neuroplasticity. Five of the included studies reported that ketamine reversed abnormal silencing of genes linked to synaptic signaling and the stress response, including the BDNF gene itself.¹⁹

Epigenetic changes are potentially more durable than individual dendritic spines, which can be formed and lost within days. If ketamine flips a switch that keeps BDNF expression elevated, the benefits to synaptic health could persist even after the drug is gone. This remains speculative in the context of PTSD specifically, since most of the epigenetic research has been conducted in depression models. But the overlap in underlying neurobiology makes it plausible that the same mechanisms are in play.

EEG Signatures as a Window Into the Brain

One practical challenge in ketamine treatment for PTSD is figuring out who is responding and why, without needing expensive brain imaging. EEG, which measures electrical brain activity through scalp electrodes, may offer a more accessible window. A study comparing ketamine’s EEG effects across PTSD, major depression, and obsessive-compulsive disorder found that the brain’s electrical response was diagnosis-specific. Patients with treatment-resistant PTSD showed dose-dependent and frequency-specific changes in EEG power, with the strongest effects in the alpha frequency band at the lowest dose tested. Patients with treatment-resistant depression, by contrast, did not show these same patterns.²⁰

Even more interesting, the correlations between EEG changes and symptom improvement differed depending on which symptom scale was being measured. This suggests that ketamine is not doing one generic thing to the brain that helps all conditions equally. Instead, the drug appears to engage different neural circuits in different disorders, and EEG could eventually help clinicians track these specific effects in real time. For a treatment that currently relies largely on subjective symptom reports to judge whether it is working, an objective brain-based biomarker would be a significant advance.